Drug Details
GB0139 (formerly TD139) is a galectin-3 inhibitor administered by dry powder inhalation.
Study Purpose
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of TD139.
